TT-00920

TransThera Sciences (Nanjing), Inc. · Phase 1 active Small molecule

At a glance

Generic name	TT-00920
Sponsor	TransThera Sciences (Nanjing), Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects (PHASE1)
A Phase 1 Study of TT-00920 in Healthy Subjects (PHASE1)
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TT-00920 CI brief — competitive landscape report
TT-00920 updates RSS · CI watch RSS
TransThera Sciences (Nanjing), Inc. portfolio CI